After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …

Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

Vaccines are an important tool in the rapidly evolving repertoire of immunotherapies in
oncology. Although cancer vaccines have been investigated for over 30 years, very few …

The development of therapeutic cancer vaccines has been pursued for many decades.
Many vaccines can elicit immunity to tumour antigens, although their clinical efficacy …

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

There are strong biologic and preclinical rationales for the development of therapeutic
cancer vaccines; however, the clinical translation of this treatment strategy has been …

Until now, three types of well‐recognized cancer treatments have been developed, ie,
surgery, chemotherapy, and radiotherapy; these either remove or directly attack the cancer …

Cancer vaccines have been shown clinically to drive tumor-reactive cell activation,
proliferation, and effector function. Unfortunately, tumor eradication by treatment with cancer …

The advent of cancer immunotherapy has revolutionized the field of cancer treatment and
offers cancer patients new hope. Although this therapy has proved highly successful for …